血清半乳糖凝集素3水平与慢性心力衰竭及其预后关系的Meta分析

doi:10.13481/j.1671-587x.20150624

摘要/Abstract

摘要：

目的:通过Meta分析方法评价新近推荐的慢性心力衰竭标志物——血清半乳糖凝集素3(Gal-3)与慢性心力衰竭的预后关系。方法:选择PubMed数据库、EMbase数据库和中国生物医学文献数据库等权威数据库,检索关于Gal-3与GHF预后关系的中、英文文献,按制定的纳入标准与排除标准筛选文献,提取风险比(HR)及其 95%可信区间(CI)。对纳入的文献进行质量评价,采用 STATA 12.1软件进行 Meta 分析,并进行敏感性分析和发表偏倚分析评价结果的稳定性和可靠性。结果:最终纳入10篇符合要求的文献,均为英文文献。1在未排除其他影响预后因素的单变量分析时,异质性分析显示 P=0.000,I²=89.2%,异质性检验表明研究具有异质性,故采用随机效应模型合并统计量,单变量分析的 HR合并后数值为1.36,95% CI:1.23~1.50。2在排除其他影响因素的多变量分析时,异质性分析显示 P<0.001,I²=68.4%,异质性检验表明研究具有异质性,故采用随机效应模型合并统计量,多变量分析的 HR合并后数值为1.17,95% CI:1.07~1.26。3敏感性分析显示,去除样本量最大的文献,单变量分析的HR合并后数值为1.54,95% CI:1.32~1.77;多变量分析的HR合并后数值为1.26,95% CI:1.09~1.42;去除样本量最小的文献,单变量分析的HR合并后数值为1.34,95% CI:1.20~1.47;多变量分析的HR合并后数值为 1.15,95% CI:1.06~1.24。结论:CHF患者血清Gal-3水平明显升高,可作为 CHF 不良预后的独立预测因子。

关键词: 慢性心力衰竭, 半乳糖凝集素-3, 全因死亡率, Meta 分析

Abstract:

Objective To evaluate the relationship between the newly recominended chronic heart failue(CHF) marker-serum galection-3(Gal-3) level and the prognosis of CHF by Meta-analysis. Methods The Chinese and English literatures about the relationship between Gal-3 and CHF prognosis were searched in PubMed,EMbase,Chinese Biomedical Literature Databases.All literatures were assessed by the inclusion and exclusion criteria.Hazard ratio (HR) and 95% confidence interval (CI) in each literature were extracted for Meta-analysis using STATA 12.1 software.The stability and reliability were evaluated by sensitivity analysis and publication bias analysis. Results Ten literatures complying with the requirements were included.The results of heterogeneity test were as follows: ① When the influence of other factors were not excluded, heterogeneity test showed that P=0.000, I²=89.2%, heterogeneity existed in different studies, so statistics were combined using a random effects model. The combined HR of univariate analysis was 1.36 and 95% CI was 1.23-1.50. 2. When the influence of other factors were excluded, heterogeneity test showed that P<0.001,I²=68.4%, heterogeneity existed in different studies, so statistics were combined using a random effects model. The combined HR of multivariate analysis was 1.17 and 95% CI was 1.07-1.26. 3. Sensitivity analysis showed that when the study with the largest samples was excluded, the combined HR of univariate analysis was 1.54 and 95% CI was 1.32-1.77; the combined HR of multivariate analysis was 1.26 and 95% CI was 1.09-1.42. When the study with the smallest samples was excluded, the combined HR of univariate analysis was 1.34 and 95% CI was 1.20-1.47; the combined HR of multivariate analysis was 1.15 and 95% CI was 1.06-1.24. Conclusion The serum level of Gal-3 is increased significantly in the patients with CHF and it may be an independent risk factor for poor prognosis of the CHF patients.

Key words: chronic heart failure, galectin 3, all cause mortality, Meta-analysis

中图分类号:

R541.4

裕晓玲, 刘振江, 秦玲. 血清半乳糖凝集素3水平与慢性心力衰竭及其预后关系的Meta分析[J]. 吉林大学学报(医学版), 2015, 41(06): 1224-1229.

YU Xiaoling, LIU Zhenjiang, QIN Ling. Relationship between serum levels of galectin-3 and prognosis of patients with chronic heart failure:A Meta-analysis[J]. Journal of Jilin University Medicine Edition, 2015, 41(06): 1224-1229.

参考文献

[1] Pal SN,Kofidis T.New cell therapies in cardiology[J].Expert Rev Cardiovasc Ther,2012,10(8):1023-1037.

[2] Emdin M,Vittorini S,Passino C.Old and new biomarkers of heart failure[J].Eur J Heart Fail,2009,11(4):331-335.

[3] Eurlings LW,Sanders-van Wijk S,van Kimmenade R,et al.multimarker strategy for short-term risk assessment in patients with dyspnea in the Emergency Department[J].Am Coll Cardiol,2012,60(17):1668-1677.

[4] 施冰,冬兰,尹秋生,等.半乳糖凝集素3在老年收缩功能正常心力衰竭患者中的临床价值[J].中华老年心脑血管病杂志,2014,16(1):12-14.

[5] Bayes-Genis A,de Antonio M,Vila J,et al.Head-to-Head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification[J].J Am Coll of Cardiol,2014,63(2):158-166.

[6] 张育民,李庆宽,全勇,等.半乳糖凝集素-3对慢性心力衰竭的诊断价值[J].中国医师杂志,2013,15(11):1446-1449.

[7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):P98-122.

[8] Felker GM,Fiuzat M,Shaw LK,et al.Galectin-3 in ambulatory patients with heart failure:results from the HF-ACTION study[J].Circ Heart Fail,2012,5(1):72-78.

[9] Tang WH,Shrestha K,Shao Z,et al.Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival[J].Am J Cardiol,2011,108(3):385-390.

[10] Lok DJ,Klip IT,Lok SI,et al.Incremental prognostic nower of Novel biomarkers (growth-differentiation factor-15,high-sensitivity C-reactive protein,galectin-3,and high-sensitivity troponin-T) in patients with advanced chronic heart failure[J].Am J Cardiol,2013,112(6):831-837.

[11] Ueland T,Aukrust P,Broch K,et al.Galectin-3 in heart failure:high levels are associated with all-cause mortality[J].Int J Cardiol,2011,150(3):361-364.

[12] Van der Velde AG,Gullestad L,Ueland T,et al.prognostic value of changes in galectin-3 levels over time in patients with heart failure:Data from CORONA and COACH[J].Circ Heart Fail,2013,6(2):219-226.

[13] Gullestad L,Ueland T,Kjekshus J,et al.The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)[J].Am Heart J,2012,164(6):878-883.

[14] de Boer RA,Lok DJ,Jaarsma T,et al.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction[J].Ann Med,2011,43(1):60-68.

[15] Carrasco-Sánchez FJ, Aramburu-Bodas O, Salamanca-Bautista P,et al.Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction[J].Int J Cardioly,2013,169(3):177-182.

[16] Anand IS,Rector TS,Kuskowski M,et al.Baseline and serial measurements of galectin-3 in patients with heart failure:relationship to prognosis and effect of treatment with valsartan in the Val-HeFT[J].Eur J of Heart Fail,2013,15(5):511-518.

[17] LokDJ,Van Der Meer P,dela Porte PW,et al.Prognostic value of galectin-3,a novel marker of fibrosis,in patients with chronic heart failure:data from the DEAL-HF study[J].Clini Res Cardiol,2010,99(55):323-328.

[18] Battistoni A,Rubattu S,Volpe M,et al.Circulating biomarkers with preventive,diagnostic and prognostic implications in cardiovascular diseases[J].Int J Cardiol, 157(2):160-168.

[19] Böhm M,Voors AA,Ketelslegers JM,et al.Biomarkers:optimizing treatment guidance in heart failure[J].Clini Res Cardiol,2011,100(11):973-981.

[20] 周恒,唐其柱,代佳,等.血清半乳糖凝集素-3 水平与慢性心力衰竭患者预后关系的 Meta 分析[J].中华临床医师杂志,2013,7(23): 10809-10813.